DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

Phase 2

Completed

Conditions: Recurrent Head and Neck Cancer
Metastatic Head and Neck Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-06-15

Last Posted Date: 2021-03-02

Lead Sponsor: UNICANCER

Target Recruit Count: 31

Registration Number: NCT01620242

Locations: 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷
Centre Antoine Lacassagne, Nice, France

and more 2 locations

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: HORMONOTHERAPY
Drug: CHEMOTHERAPY then HORMONOTHERAPY

First Posted Date: 2012-03-27

Last Posted Date: 2024-05-17

Lead Sponsor: UNICANCER

Target Recruit Count: 1989

Registration Number: NCT01564056

Locations: 🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇧🇪
Grand Hopital de Charleroi (GHdC), Charleroi, Belgium
🇧🇪
CHU Ambroise Paré, Mons, Belgium

and more 81 locations

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

Phase 3

Completed

Conditions: Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)

Interventions: Drug: mFolfirinox
Drug: Gemcitabine

First Posted Date: 2012-02-03

Last Posted Date: 2022-01-04

Lead Sponsor: UNICANCER

Target Recruit Count: 493

Registration Number: NCT01526135

Locations: 🇫🇷
CH Layné, Mont de Marsan, France
🇨🇦
Dr Leon Richard Oncology Centre, Moncton, New Brunswick, Canada
🇫🇷
CHU De ST Eloi, Montpellier, France

and more 48 locations

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Phase 2

Completed

Conditions: Malignant Neoplasm of Esophagus
Malignant Neoplasm of Stomach

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-fluoro-uracil
Drug: panitumumab
Drug: AMG102

First Posted Date: 2011-09-29

Last Posted Date: 2020-11-17

Lead Sponsor: UNICANCER

Target Recruit Count: 162

Registration Number: NCT01443065

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Folinic Acid
Drug: Oxaliplatin
Drug: 5-FU
Drug: Irinotecan
Drug: Bevacizumab
Drug: Cetuximab

First Posted Date: 2011-09-29

Last Posted Date: 2021-06-18

Lead Sponsor: UNICANCER

Target Recruit Count: 256

Registration Number: NCT01442935

Locations: 🇫🇷
Centre Val d'Aurelle, Montpellier, France

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Phase 3

Active, not recruiting

Conditions: Metastases

Interventions: Drug: Leuprorelin Acetate

First Posted Date: 2011-09-28

Last Posted Date: 2023-06-22

Lead Sponsor: UNICANCER

Target Recruit Count: 700

Registration Number: NCT01442246

Locations: 🇫🇷
Chu Bordeaux- Hopital Pellegrin, Bordeaux, France
🇫🇷
Clinique Victor Pauchet, Amiens, France
🇫🇷
Chu Besancon, Besancon, France

and more 32 locations

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Phase 2

Completed

Conditions: Leiomyosarcoma

Interventions: Drug: pazopanib + gemcitabine

First Posted Date: 2011-09-28

Last Posted Date: 2020-01-31

Lead Sponsor: UNICANCER

Target Recruit Count: 106

Registration Number: NCT01442662

Locations: 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Institut Curie - Hopital René Huguenin, Saint Cloud, France

and more 14 locations

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-fluoro-uracil
Drug: Irinotecan
Drug: Bevacizumab
Drug: Cetuximab

First Posted Date: 2011-09-28

Last Posted Date: 2022-01-11

Lead Sponsor: UNICANCER

Target Recruit Count: 133

Registration Number: NCT01442649

Locations: 🇫🇷
Centre rené Gauducheau, Saint-herblain, France

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: Afatinib

First Posted Date: 2011-08-12

Last Posted Date: 2022-02-02

Lead Sponsor: UNICANCER

Target Recruit Count: 61

Registration Number: NCT01415674

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Institut de cancérologie de l'Ouest - Site Paul Papin, Angers, France

and more 8 locations

High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2011-08-11

Last Posted Date: 2017-05-04

Lead Sponsor: UNICANCER

Target Recruit Count: 423

Registration Number: NCT01414933

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Centre Georges François Leclerc, Dijon, France

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy